Trial · NCT07898813
Daraxonrasib in Resectable PDAC
NCT07898813, Phase 1, Not yet recruiting, Dana-Farber Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Daraxonrasib in Resectable PDAC. Trials, record NCT07898813. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898813
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Daraxonrasib in Resectable PDAC
- NCT number
- NCT07898813
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Dana-Farber Cancer Institute
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Daraxonrasib, Surgical Resection, Adjuvant Chemotherapy, Adjuvant Radiation Therapy
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Successful Receipt of Surgery Rate | After 6- or 12-weeks of neoadjuvant therapy | Proportion of participants who complete neoadjuvant darazonrasib therapy and then attempt surgery. |
| Secondary | R0 Resection Rate | After 6- or 12-weeks of neoadjuvant therapy | Proportion of participants who undergo surgery after completing neoadjuvant darazonrasib therapy and achieve negative margin (R0) resection status. |
| Secondary | Objective Response Rate (ORR) | After 6- or 12-weeks of neoadjuvant therapy | ORR is defined as the proportion of participants achieving complete response (CR) or partial response (PR) on neoadjuvant darazonrasib therapy. Per RECIST 1.1 criteria for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. |
| Secondary | Disease Control Rate (DCR) | After 6- or 12-weeks of neoadjuvant therapy | DCR is defined as the proportion of participants achieving CR, PR or stable disease (SD) on neoadjuvant darazonrasib therapy. Per RECIST 1.1 criteria: SD is not achieving PR or experiencing disease progression (PD). PD per RECIST 1.1 for target lesions is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. |
| Secondary | Pathologic Response Rate | After 6- or 12-weeks of neoadjuvant therapy | Proportion of participants who achieve pathologic response defined as tumor regression of grades 0 or 1 in all participants who underwent resection based on evaluation of the resected pancreatic tumor specimen by an experienced pathologist as reported according to College of American Pathologist guidelines (2012). |
| Secondary | Grade 3-4 Adverse Event Rate | After 6- or 12-weeks of neoadjuvant therapy | Proportion of participants who experience a grade 3 or 4 adverse event on neoadjuvant darazonrasib therapy as measured by CTCAE version 5. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898813
GET https://conductscience.org/api/trials/v1/NCT07898813/registered